nach oben

Erschienen in:

12.08.2021 | Clinical trial

A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density

verfasst von: Edgar Tapia, Diana Evelyn Villa-Guillen, Pavani Chalasani, Sara Centuori, Denise J. Roe, Jose Guillen-Rodriguez, Chuan Huang, Jean-Phillippe Galons, Cynthia A. Thomson, Maria Altbach, Jesse Trujillo, Liane Pinto, Jessica A. Martinez, Amit M. Algotar, H-H. Sherry Chow

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Obesity is a known risk factor for post-menopausal breast cancer and may increase risk for triple negative breast cancer in premenopausal women. Intervention strategies are clearly needed to reduce obesity-associated breast cancer risk.

Methods

We conducted a Phase II double-blind, randomized, placebo-controlled trial of metformin in overweight/obese premenopausal women with components of metabolic syndrome to assess the potential of metformin for primary breast cancer prevention. Eligible participants were randomized to receive metformin (850 mg BID, n = 76) or placebo (n = 75) for 12 months. Outcomes included breast density, assessed by fat/water MRI with change in percent breast density as the primary endpoint, anthropometric measures, and intervention feasibility.

Results

Seventy-six percent in the metformin arm and 83% in the placebo arm (p = 0.182) completed the 12-month intervention. Adherence to study agent was high with more than 80% of participants taking ≥ 80% assigned pills. The most common adverse events reported in the metformin arm were gastrointestinal in nature and subsided over time. Compared to placebo, metformin intervention led to a significant reduction in waist circumference (p < 0.001) and waist-to-hip ratio (p = 0.019). Compared to placebo, metformin did not change percent breast density and dense breast volume but led to a numerical but not significant decrease in non-dense breast volume (p = 0.070).

Conclusion

We conclude that metformin intervention resulted in favorable changes in anthropometric measures of adiposity and a borderline decrease in non-dense breast volume in women with metabolic dysregulation. More research is needed to understand the impact of metformin on breast cancer risk reduction.

Trial registration

ClinicalTrials.gov NCT02028221. Registered January 7, 2014, https://clinicaltrials.gov/ct2/show/NCT02028221

Nur mit Berechtigung zugänglich

Flegal KM et al (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307(5):491–497PubMedCrossRef

van den Brandt PA et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152(6):514–527PubMedCrossRef

Cheraghi Z et al (2012) Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS ONE 7(12):e51446PubMedPubMedCentralCrossRef

Anderson GL, Neuhouser ML (2012) Obesity and the risk for premenopausal and postmenopausal breast cancer. Cancer Prev Res (Phila) 5(4):515–521CrossRef

Berstad P et al (2010) A case-control study of body mass index and breast cancer risk in white and African-American women. Cancer Epidemiol Biomarkers Prev 19(6):1532–1544PubMedPubMedCentralCrossRef

Harris HR et al (2011) Body fat distribution and risk of premenopausal breast cancer in the nurses’ health study II. J Natl Cancer Inst 103(3):273–278PubMedCrossRef

Pierobon M, Frankenfeld CL (2013) Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 137(1):307–314PubMedCrossRef

Samuel SM et al (2019) Metformin: the answer to cancer in a flower? Current knowledge and future prospects of metformin as an anti-cancer agent in breast cancer. Biomolecules 9(12):846PubMedCentralCrossRef

Zakikhani M et al (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 1(5):369–375CrossRef

10.

Phoenix KN, Vumbaca F, Claffey KP (2009) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113(1):101–111PubMedCrossRef

11.

Alimova IN et al (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8(6):909–915PubMedCrossRef

12.

Liu B et al (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8(13):2031–2040PubMedCrossRef

13.

Anisimov VN et al (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40(8–9):685–693PubMedCrossRef

14.

Libby G et al (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32(9):1620–1625PubMedPubMedCentralCrossRef

15.

Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766–1777PubMedCrossRef

16.

Bodmer M et al (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33(6):1304–1308PubMedPubMedCentralCrossRef

17.

Decensi A et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3(11):1451–1461CrossRef

18.

Tang GH et al (2018) Association of metformin with breast cancer incidence and mortality in patients with Type II diabetes: a grade-assessed systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 27(6):627–635PubMedCrossRef

19.

Vona-Davis L, Rose DP (2012) Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. Curr Diabetes Rev 8(2):116–130PubMedCrossRef

20.

Bonanni B et al (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30(21):2593–2600PubMedCrossRef

21.

Algire C et al (2011) Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 30(10):1174–1182PubMedCrossRef

22.

Phoenix KN et al (2010) Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat 123(2):333–344PubMedCrossRef

23.

Grundy SM et al (2005) Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 112(17):2735–2752PubMedCrossRef

24.

Martinez JA et al (2016) Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol. BMC Cancer 16:500PubMedPubMedCentralCrossRef

25.

Chatterton RT et al (2016) Nipple aspirate fluid hormone concentrations and breast cancer risk. Horm Cancer 7(2):127–136PubMedPubMedCentralCrossRef

26.

Shaheed SU et al (2018) Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer. Clin Proteomics 15:3PubMedPubMedCentralCrossRef

27.

Sauter ER (2005) Analysis of nipple aspirate fluid for diagnosis of breast cancer: an alternative to invasive biopsy. Expert Rev Mol Diagn 5(6):873–881PubMedCrossRef

28.

Nguyen MM et al (2018) Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort. Eur J Cancer Prev 27(6):557–562PubMedPubMedCentralCrossRef

29.

Zhong X et al (2014) Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging. Magn Reson Med 72(5):1353–1365PubMedCrossRef

30.

Ding J et al (2018) Reproducible automated breast density measure with no ionizing radiation using fat-water decomposition MRI. J Magn Reson Imaging 48(4):971–981PubMedPubMedCentralCrossRef

31.

Diabetes Prevention Program Research Group (2012) Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care 35(4):731–7CrossRef

32.

Diabetes Prevention Program Research Group (2015) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study. Lancet Diabetes Endocrinol 3(11):866–75PubMedCentralCrossRef

33.

Patterson RE et al (2018) The effects of metformin and weight loss on biomarkers associated with breast cancer outcomes. J Natl Cancer Inst 110(11):1239–1247PubMedPubMedCentralCrossRef

34.

Yanovski JA et al (2011) Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 60(2):477–485PubMedPubMedCentralCrossRef

35.

Stumvoll M et al (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333(9):550–554PubMedCrossRef

36.

Fay JR, Steele V, Crowell JA (2009) Energy homeostasis and cancer prevention: the AMP-activated protein kinase. Cancer Prev Res (Phila Pa) 2(4):301–309CrossRef

37.

Kato I et al (1995) A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York city, NY, United States). Cancer Causes Control 6(5):431–438PubMedCrossRef

38.

Boyd N et al (2009) Mammographic density and breast cancer risk: evaluation of a novel method of measuring breast tissue volumes. Cancer Epidemiol Biomarkers Prev 18(6):1754–1762PubMedCrossRef

39.

Pettersson A et al (2014) Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 106(5):dju078. https://doi.org/10.1093/jnci/dju078CrossRefPubMedPubMedCentral

40.

Brentnall AR et al (2020) Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. Breast Cancer Res 22(1):101PubMedPubMedCentralCrossRef

41.

Cuzick J et al (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103(9):744–752PubMedCrossRef

42.

Pettersson A et al (2011) Nondense mammographic area and risk of breast cancer. Breast Cancer Res 13(5):R100PubMedPubMedCentralCrossRef

43.

Baglietto L et al (2014) Associations of mammographic dense and nondense areas and body mass index with risk of breast cancer. Am J Epidemiol 179(4):475–483PubMedCrossRef

44.

Stone J et al (2010) Using mammographic density to predict breast cancer risk: dense area or percentage dense area. Breast Cancer Res 12(6):R97PubMedPubMedCentralCrossRef

45.

Lokate M et al (2011) Mammographic density and breast cancer risk: the role of the fat surrounding the fibroglandular tissue. Breast Cancer Res 13(5):R103PubMedPubMedCentralCrossRef

46.

Guest AR et al (2000) Adverse effects of increased body weight on quantitative measures of mammographic image quality. AJR Am J Roentgenol 175(3):805–810PubMedCrossRef

47.

Thomson CA et al (2017) A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Res Treat 165(1):97–107PubMedPubMedCentralCrossRef

48.

Thompson PA et al (2021) Sulindac, a non-selective NSAID, reduces breast density in postmenopausal women with breast cancer treated with aromatase inhibitors. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-0732CrossRefPubMedPubMedCentral

49.

Buschard K et al (2017) Diabetes, diabetes treatment, and mammographic density in Danish diet, cancer, and health cohort. Cancer Causes Control 28(1):13–21PubMedCrossRef

50.

Morris PG et al (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 4(7):1021–1029CrossRef

51.

Vaysse C et al (2017) Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer. NPJ Breast Cancer 3:19PubMedPubMedCentralCrossRef

52.

Iyengar NM et al (2017) Metabolic obesity, adipose inflammation and elevated breast aromatase in women with normal body mass index. Cancer Prev Res (Phila) 10(4):235–243CrossRef

53.

Sun X et al (2012) Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression. Breast Cancer Res Treat 131(3):1003–1012PubMedCrossRef

54.

Subbaramaiah K et al (2011) Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 4(3):329–346CrossRef

55.

Seo BR et al (2015) Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. Sci Transl Med 7(301):301ra130PubMedPubMedCentralCrossRef

56.

Springer NL et al (2019) Obesity-associated extracellular matrix remodeling promotes a macrophage phenotype similar to tumor-associated macrophages. Am J Pathol 189(10):2019–2035PubMedPubMedCentralCrossRef

Titel: A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density
verfasst von: Edgar Tapia
Diana Evelyn Villa-Guillen
Pavani Chalasani
Sara Centuori
Denise J. Roe
Jose Guillen-Rodriguez
Chuan Huang
Jean-Phillippe Galons
Cynthia A. Thomson
Maria Altbach
Jesse Trujillo
Liane Pinto
Jessica A. Martinez
Amit M. Algotar
H-H. Sherry Chow
Publikationsdatum: 12.08.2021
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-021-06355-9

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A randomized controlled trial of metformin in women with components of metabolic syndrome: intervention feasibility and effects on adiposity and breast density